Liver Cancer - Pipeline Review, H2 2015


#553596

1113pages

Global Markets Direct

$ 2500

In Stock

Liver Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Liver Cancer - Pipeline Review, H2 2015, provides an overview of the Liver Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Liver Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 9
Liver Cancer Overview 10
Therapeutics Development 11
Liver Cancer - Therapeutics under Development by Companies 13
Liver Cancer - Therapeutics under Investigation by Universities/Institutes 28
Liver Cancer - Pipeline Products Glance 31
Liver Cancer - Products under Development by Companies 34
Liver Cancer - Products under Investigation by Universities/Institutes 53
Liver Cancer - Companies Involved in Therapeutics Development 56
Liver Cancer - Therapeutics Assessment 224
Drug Profiles 246
Liver Cancer - Recent Pipeline Updates 750
Liver Cancer - Dormant Projects 1055
Liver Cancer - Discontinued Products 1070
Liver Cancer - Product Development Milestones 1074
Appendix 1081

List of Tables
Number of Products under Development for Liver Cancer, H2 2015 42
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2015 43
Number of Products under Development by Companies, H2 2015 45
Number of Products under Development by Companies, H2 2015 (Contd..1) 46
Number of Products under Development by Companies, H2 2015 (Contd..2) 47
Number of Products under Development by Companies, H2 2015 (Contd..3) 48
Number of Products under Development by Companies, H2 2015 (Contd..4) 49
Number of Products under Development by Companies, H2 2015 (Contd..5) 50
Number of Products under Development by Companies, H2 2015 (Contd..6) 51
Number of Products under Development by Companies, H2 2015 (Contd..7) 52
Number of Products under Development by Companies, H2 2015 (Contd..8) 53
Number of Products under Development by Companies, H2 2015 (Contd..9) 54
Number of Products under Development by Companies, H2 2015 (Contd..10) 55
Number of Products under Development by Companies, H2 2015 (Contd..11) 56
Number of Products under Development by Companies, H2 2015 (Contd..12) 57
Number of Products under Development by Companies, H2 2015 (Contd..13) 58
Number of Products under Investigation by Universities/Institutes, H2 2015 59
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 60
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 61
Comparative Analysis by Late Stage Development, H2 2015 62
Comparative Analysis by Clinical Stage Development, H2 2015 63
Comparative Analysis by Early Stage Development, H2 2015 64
Products under Development by Companies, H2 2015 65
Products under Development by Companies, H2 2015 (Contd..1) 66
Products under Development by Companies, H2 2015 (Contd..2) 67
Products under Development by Companies, H2 2015 (Contd..3) 68
Products under Development by Companies, H2 2015 (Contd..4) 69
Products under Development by Companies, H2 2015 (Contd..5) 70
Products under Development by Companies, H2 2015 (Contd..6) 71
Products under Development by Companies, H2 2015 (Contd..7) 72
Products under Development by Companies, H2 2015 (Contd..8) 73
Products under Development by Companies, H2 2015 (Contd..9) 74
Products under Development by Companies, H2 2015 (Contd..10) 75
Products under Development by Companies, H2 2015 (Contd..11) 76
Products under Development by Companies, H2 2015 (Contd..12) 77
Products under Development by Companies, H2 2015 (Contd..13) 78
Products under Development by Companies, H2 2015 (Contd..14) 79
Products under Development by Companies, H2 2015 (Contd..15) 80
Products under Development by Companies, H2 2015 (Contd..16) 81
Products under Development by Companies, H2 2015 (Contd..17) 82
Products under Development by Companies, H2 2015 (Contd..18) 83
Products under Investigation by Universities/Institutes, H2 2015 84
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 85
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 86
Liver Cancer - Pipeline by 4SC AG, H2 2015 87
Liver Cancer - Pipeline by AB Science SA, H2 2015 88
Liver Cancer - Pipeline by AbbVie Inc., H2 2015 89
Liver Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015 90
Liver Cancer - Pipeline by ACROVIS Pharma AG, H2 2015 91
Liver Cancer - Pipeline by Adaptimmune Limited, H2 2015 92
Liver Cancer - Pipeline by Aduro BioTech, Inc., H2 2015 93
Liver Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2015 94
Liver Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015 95
Liver Cancer - Pipeline by Alfact Innovation, H2 2015 96
Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 97
Liver Cancer - Pipeline by American Gene Technologies International Inc., H2 2015 98
Liver Cancer - Pipeline by Amgen Inc., H2 2015 99
Liver Cancer - Pipeline by AndroScience Corporation, H2 2015 100
Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H2 2015 101
Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H2 2015 102
Liver Cancer - Pipeline by ArQule, Inc., H2 2015 103
Liver Cancer - Pipeline by Array BioPharma Inc., H2 2015 104
Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2015 105
Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 106
Liver Cancer - Pipeline by AstraZeneca Plc, H2 2015 107
Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 108
Liver Cancer - Pipeline by Bayer AG, H2 2015 109
Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2015 110
Liver Cancer - Pipeline by BioCancell Ltd, H2 2015 111
Liver Cancer - Pipeline by Biogazelle, H2 2015 112
Liver Cancer - Pipeline by Bioneer Corporation, H2 2015 113
Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H2 2015 114
Liver Cancer - Pipeline by Blueprint Medicines, H2 2015 115
Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 116
Liver Cancer - Pipeline by Boston Biomedical, Inc., H2 2015 117
Liver Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 118
Liver Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015 119
Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H2 2015 120
Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015 121
Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2015 122
Liver Cancer - Pipeline by Celgene Corporation, H2 2015 123
Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 124
Liver Cancer - Pipeline by Celsion Corporation, H2 2015 125
Liver Cancer - Pipeline by China Medical System Holdings Limited, H2 2015 126
Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015 127
Liver Cancer - Pipeline by Chroma Therapeutics Limited, H2 2015 128
Liver Cancer - Pipeline by CohBar, Inc., H2 2015 129
Liver Cancer - Pipeline by CrystalGenomics, Inc., H2 2015 130
Liver Cancer - Pipeline by CytRx Corporation, H2 2015 131
Liver Cancer - Pipeline by CZ BioMed Corp, H2 2015 132
Liver Cancer - Pipeline by Delcath Systems, Inc., H2 2015 133
Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015 134
Liver Cancer - Pipeline by Digna Biotech, S.L., H2 2015 135
Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2015 136
Liver Cancer - Pipeline by e-Therapeutics Plc, H2 2015 137
Liver Cancer - Pipeline by Eisai Co., Ltd., H2 2015 138
Liver Cancer - Pipeline by Eli Lilly and Company, H2 2015 139
Liver Cancer - Pipeline by Endocyte, Inc., H2 2015 140
Liver Cancer - Pipeline by Erytech Pharma SA, H2 2015 141
Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H2 2015 142
Liver Cancer - Pipeline by Exelixis, Inc., H2 2015 143
Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 144
Liver Cancer - Pipeline by Genelux Corporation, H2 2015 145
Liver Cancer - Pipeline by Genoscience Pharma, H2 2015 146
Liver Cancer - Pipeline by GenSpera, Inc., H2 2015 147
Liver Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 148
Liver Cancer - Pipeline by Golden Biotechnology Corp., H2 2015 149
Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 150
Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015 151
Liver Cancer - Pipeline by Horizon Pharma Plc, H2 2015 152
Liver Cancer - Pipeline by Huperion Sarl, H2 2015 153
Liver Cancer - Pipeline by Immunicum AB, H2 2015 154
Liver Cancer - Pipeline by Immunitor, Inc., H2 2015 155
Liver Cancer - Pipeline by Immunomedics, Inc., H2 2015 156
Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2015 157
Liver Cancer - Pipeline by Immuron Limited, H2 2015 158
Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H2 2015 159
Liver Cancer - Pipeline by In-Cell-Art S.A.S., H2 2015 160
Liver Cancer - Pipeline by Incanthera Ltd., H2 2015 161
Liver Cancer - Pipeline by Incuron, LLC, H2 2015 162
Liver Cancer - Pipeline by InteRNA Technologies B.V., H2 2015 163
Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015 164
Liver Cancer - Pipeline by Jenrin Discovery, Inc., H2 2015 165
Liver Cancer - Pipeline by Johnson & Johnson, H2 2015 166
Liver Cancer - Pipeline by JSK Therapeutics Inc., H2 2015 167
Liver Cancer - Pipeline by KAHR medical Ltd., H2 2015 168
Liver Cancer - Pipeline by Keystone Nano, Inc., H2 2015 169
Liver Cancer - Pipeline by Kite Pharma, Inc., H2 2015 170
Liver Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015 171
Liver Cancer - Pipeline by Kowa Company, Ltd., H2 2015 172
Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015 173
Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 174
Liver Cancer - Pipeline by LivTech, Inc., H2 2015 175
Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 176
Liver Cancer - Pipeline by Lytix Biopharma AS, H2 2015 177
Liver Cancer - Pipeline by MaxCyte, Inc., H2 2015 178
Liver Cancer - Pipeline by MedImmune, LLC, H2 2015 179
Liver Cancer - Pipeline by Medivation, Inc., H2 2015 180
Liver Cancer - Pipeline by Medivir AB, H2 2015 181
Liver Cancer - Pipeline by Merck KGaA, H2 2015 182
Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 183
Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 184
Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015 185
Liver Cancer - Pipeline by MolMed S.p.A., H2 2015 186
Liver Cancer - Pipeline by MultiCell Technologies, Inc., H2 2015 187
Liver Cancer - Pipeline by NeoPharm Co., Ltd., H2 2015 188
Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H2 2015 189
Liver Cancer - Pipeline by NormOxys, Inc., H2 2015 190
Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2015 191
Liver Cancer - Pipeline by Novartis AG, H2 2015 192
Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H2 2015 193
Liver Cancer - Pipeline by Omeros Corporation, H2 2015 194
Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015 195
Liver Cancer - Pipeline by Oncology Research International Limited, H2 2015 196
Liver Cancer - Pipeline by Oncolys BioPharma Inc., H2 2015 197
Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015 198
Liver Cancer - Pipeline by OncoTherapy Science, Inc., H2 2015 199
Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H2 2015 200
Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 201
Liver Cancer - Pipeline by Onxeo SA, H2 2015 202
Liver Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 203
Liver Cancer - Pipeline by OPKO Health, Inc., H2 2015 204
Liver Cancer - Pipeline by Orega Biotech SAS, H2 2015 205
Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 206
Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015 207
Liver Cancer - Pipeline by Peptinov SAS, H2 2015 208
Liver Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015 209
Liver Cancer - Pipeline by Pfizer Inc., H2 2015 210
Liver Cancer - Pipeline by Pharma Mar, S.A., H2 2015 211
Liver Cancer - Pipeline by PharmAbcine, Inc., H2 2015 212
Liver Cancer - Pipeline by PharmaEssentia Corporation, H2 2015 213
Liver Cancer - Pipeline by PhaseRx, Inc., H2 2015 214
Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2015 215
Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 216
Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H2 2015 217
Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H2 2015 218
Liver Cancer - Pipeline by Provecs Medical GmbH, H2 2015 219
Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015 220
Liver Cancer - Pipeline by Qu Biologics Inc., H2 2015 221
Liver Cancer - Pipeline by Quimatryx, S.L., H2 2015 222
Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H2 2015 223
Liver Cancer - Pipeline by RedHill Biopharma Ltd., H2 2015 224
Liver Cancer - Pipeline by Regen BioPharma, Inc., H2 2015 225
Liver Cancer - Pipeline by Regulus Therapeutics Inc., H2 2015 226
Liver Cancer - Pipeline by Rigontec GmbH, H2 2015 227
Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H2 2015 228
Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2015 229
Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H2 2015 230
Liver Cancer - Pipeline by Silence Therapeutics Plc, H2 2015 231
Liver Cancer - Pipeline by Sillajen Biotherapeutics, H2 2015 232
Liver Cancer - Pipeline by Sirnaomics, Inc., H2 2015 233
Liver Cancer - Pipeline by Synovo GmbH, H2 2015 234
Liver Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 235
Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2015 236
Liver Cancer - Pipeline by Targetome, H2 2015 237
Liver Cancer - Pipeline by Therapure Biopharma Inc., H2 2015 238
Liver Cancer - Pipeline by Theravectys SA, H2 2015 239
Liver Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 240
Liver Cancer - Pipeline by Tiziana, H2 2015 241
Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015 242
Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 243
Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2015 244
Liver Cancer - Pipeline by Tumorend, LLC, H2 2015 245
Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H2 2015 246
Liver Cancer - Pipeline by Vaxon Biotech, H2 2015 247
Liver Cancer - Pipeline by Vect-Horus S.A.S., H2 2015 248
Liver Cancer - Pipeline by Verlyx Pharma Inc., H2 2015 249
Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H2 2015 250
Liver Cancer - Pipeline by Virttu Biologics Limited, H2 2015 251
Liver Cancer - Pipeline by Viventia Bio Inc., H2 2015 252
Liver Cancer - Pipeline by Welichem Biotech Inc., H2 2015 253
Liver Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015 254
Assessment by Monotherapy Products, H2 2015 255
Assessment by Combination Products, H2 2015 256
Number of Products by Stage and Target, H2 2015 258
Number of Products by Stage and Mechanism of Action, H2 2015 267
Number of Products by Stage and Route of Administration, H2 2015 274
Number of Products by Stage and Molecule Type, H2 2015 276
Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2015 781
Liver Cancer - Dormant Projects, H2 2015 1087
Liver Cancer - Dormant Projects (Contd..1), H2 2015 1088
Liver Cancer - Dormant Projects (Contd..2), H2 2015 1089
Liver Cancer - Dormant Projects (Contd..3), H2 2015 1090
Liver Cancer - Dormant Projects (Contd..4), H2 2015 1091
Liver Cancer - Dormant Projects (Contd..5), H2 2015 1092
Liver Cancer - Dormant Projects (Contd..6), H2 2015 1093
Liver Cancer - Dormant Projects (Contd..7), H2 2015 1094
Liver Cancer - Dormant Projects (Contd..8), H2 2015 1095
Liver Cancer - Dormant Projects (Contd..9), H2 2015 1096
Liver Cancer - Dormant Projects (Contd..10), H2 2015 1097
Liver Cancer - Dormant Projects (Contd..11), H2 2015 1098
Liver Cancer - Dormant Projects (Contd..12), H2 2015 1099
Liver Cancer - Dormant Projects (Contd..13), H2 2015 1100
Liver Cancer - Dormant Projects (Contd..14), H2 2015 1101
Liver Cancer - Discontinued Products, H2 2015 1102
Liver Cancer - Discontinued Products (Contd..1), H2 2015 1103
Liver Cancer - Discontinued Products (Contd..2), H2 2015 1104
Liver Cancer - Discontinued Products (Contd..3), H2 2015 1105

List of Figures
Number of Products under Development for Liver Cancer, H2 2015 42
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2015 43
Number of Products under Development by Companies, H2 2015 44
Number of Products under Investigation by Universities/Institutes, H2 2015 59
Comparative Analysis by Clinical Stage Development, H2 2015 63
Comparative Analysis by Early Stage Products, H2 2015 64
Assessment by Monotherapy Products, H2 2015 255
Assessment by Combination Products, H2 2015 256
Number of Products by Top 10 Targets, H2 2015 257
Number of Products by Stage and Top 10 Targets, H2 2015 257
Number of Products by Top 10 Mechanism of Actions, H2 2015 266
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 266
Number of Products by Top 10 Routes of Administration, H2 2015 273
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 273
Number of Products by Top 10 Molecule Types, H2 2015 275
Number of Products by Stage and Top 10 Molecule Types, H2 2015 275